GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,423.00GBp
12:07pm EDT
Price Change (% chg)

-46.50p (-3.16%)
Prev Close
1,469.50p
Open
1,456.00p
Day's High
1,458.50p
Day's Low
1,417.00p
Volume
14,329,966
Avg. Vol
7,631,166
52-wk High
1,733.00p
52-wk Low
1,417.00p

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in... (more)

Overall

Beta: 0.48
Market Cap (Mil.): £71,254.95
Shares Outstanding (Mil.): 4,848.92
Dividend: 19.00
Yield (%): 5.44

Financials

  GSK.L Industry Sector
P/E (TTM): 13.99 35.80 36.21
EPS (TTM): 1.05 -- --
ROI: 18.60 18.99 18.26
ROE: 77.28 19.76 19.13
Search Stocks

Banks outperform Britain's FTSE after RBS's bumper results

LONDON, July 25 - British lenders who focus on the domestic market outperformed a slightly negative FTSE 100 index on Friday after strong results from Royal Bank of Scotland and solid economic growth data.

11:29am EDT

Banks outpace flat UK FTSE after RBS's bumper results

LONDON, July 25 - British lenders who focus on the domestic market outpaced a flat FTSE 100 index on Friday after strong results from Royal Bank of Scotland and solid economic output data.

6:29am EDT

Exclusive: Allegations of GSK corruption spread to Syria

LONDON - GlaxoSmithKline faces new allegations of corruption, this time in Syria, where the drugmaker and its distributor have been accused of paying bribes to secure business, according to a whistleblower's email reviewed by Reuters.

24 Jul 2014

GSK seeks approval for world's first malaria vaccine

LONDON - GlaxoSmithKline said on Thursday it is applying for regulatory approval for the world's first vaccine against malaria, designed for children in Africa.

24 Jul 2014

UPDATE 2-GSK seeks approval for world's first malaria vaccine

* Mosquito-borne malaria kills over 600,000 people a year

24 Jul 2014

Atox Bio raises $23 million to fund flesh-eating bacteria treatment

TEL AVIV - Israel-based Atox Bio, a developer of therapeutics for severe infections, said on Thursday it has raised $23 million in an investment round led by SR One, the healthcare venture capital fund of GlaxoSmithKline.

24 Jul 2014

BRIEF-GSK makes regulatory submission to EU for malaria vaccine candidate

* Gsk announces eu regulatory submission for malaria vaccine candidate rts,s

24 Jul 2014

Atox Bio raises $23 mln to fund flesh-eating bacteria treatment

TEL AVIV, July 24 - Israel-based Atox Bio, a developer of therapeutics for severe infections, said on Thursday it has raised $23 million in an investment round led by SR One, the healthcare venture capital fund of GlaxoSmithKline .

24 Jul 2014

GSK seeks approval for world's first malaria vaccine

LONDON, July 24 - GlaxoSmithKline is applying for regulatory approval for the world's first vaccine against malaria, designed for use in children in Africa.

24 Jul 2014

BREAKINGVIEWS-GSK trapped in Big Pharma's strategic bind

(The author is a Reuters Breakingviews columnist. The opinions expressed are his own.)

23 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Plunkett Research, Ltd.
$99.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks